drugset / Trial / NCT07251062
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.
Timeline
- Start
- 2025-12-30
- Primary completion
- 2029-12-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | Oral |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Subject | Enlonstobart | Monoclonal antibody | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | SYS6010 | Monoclonal antibody | — | — |
| Comparator | Tislelizumab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |